CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Preclinical Characterization of AEG35156/GEM 640, a Second-Generation Antisense Oligonucleotide Targeting X-Linked Inhibitor of Apoptosis

Abstract

Purpose: Cancer cells can use X-linked inhibitor of apoptosis (XIAP) to evade apoptotic cues, including chemotherapy. The antitumor potential of AEG35156, a novel second-generation antisense oligonucleotide directed toward XIAP, was assessed in human cancer models when given as a single agent and in combination with clinically relevant chemotherapeutics. Experimental Design: AEG35156 was characterized for its ability to cause dose-dependent reductions of XIAP mRNA and protein in vitro and in vivo, to sensitize cancer cell lines to death stimuli, and to exhibit antitumor activity in multiple human cancer xenograft models as a single agent or in combination with chemotherapy. Results: AEG35156 reduced XIAP mRNA levels with an EC50 of 8 to 32 nmol/L and decreased XIAP protein levels by >80%. Loss of XIAP protein correlated with increased sensitization to tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)–mediated apoptosis in Panc-1 pancreatic carcinoma cells. AEG35156 exhibited potent antitumor activity relative to control oligonucleotides in three human cancer xenograft models (prostate, colon, and lung) and was capable of inducing complete tumor regression when combined with taxanes. Antitumor effects of AEG35156 correlated with suppression of tumor XIAP levels. Conclusions: AEG35156 reduces XIAP levels and sensitizes tumors to chemotherapy. AEG35156 is presently under clinical assessment in multiple phase I trials in cancer patients as a single agent and in combination with docetaxel in solid tumors or cytarabine/idarubicin in leukemia.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-06-0608

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 58 · Cited by 128

Metadata

Authors
LaCasse, E. C., Cherton-Horvat, G. G., Hewitt, K. E., Jerome, L. J., Morris, S. J., Kandimalla, E. R., Yu, D., Wang, H., Wang, W., Zhang, R., Agrawal, S., Gillard, J. W., & Durkin, J. P.
Affiliations
  • Aegera Therapeutics (Canada) (CA)
  • Idera Pharmaceuticals (United States) (US)
  • University of Alabama at Birmingham (US)
Venue
Clinical Cancer Research
Published
2006-09-01
Volume
12
Issue
17
Pages
5231-5241
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2150323133
Cited by
128
References
58
Citations by year
2025: 1 · 2023: 1 · 2022: 2 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 10 · 2013: 10 · 2012: 9
FWCI
7.47
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
antisense oligonucleotides, XIAP, X-linked inhibitor of apoptosis, apoptosis evasion, TRAIL sensitization, chemosensitization, taxanes, docetaxel, tumor xenografts, pancreatic cancer, prostate cancer, colon cancer, lung cancer, leukemia, combination therapy
MeSH terms
Docetaxel, Animals, Antineoplastic Agents, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Screening Assays, Antitumor, Drug Synergism, Humans, Mice, Nude, Neoplasms, Oligonucleotides, RNA, Messenger, Sensitivity and Specificity, Structure-Activity Relationship, Transplantation, Heterologous, Apoptosis, Reverse Transcriptase Polymerase Chain Reaction, Oligodeoxyribonucleotides, Antisense, Gene Expression Profiling, Xenograft Model Antitumor Assays, Taxoids, Cell Line, Tumor, Mice, X-Linked Inhibitor of Apoptosis Protein, TNF-Related Apoptosis-Inducing Ligand

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical Characterization of AEG35156/GEM 640, a Second-Generation Antisense Oligonucleotide Targeting X-Linked Inhibitor of Apoptosis. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-06-0608
The paper
LaCasse, E. C., Cherton-Horvat, G. G., Hewitt, K. E., Jerome, L. J., Morris, S. J., Kandimalla, E. R., Yu, D., Wang, H., Wang, W., Zhang, R., Agrawal, S., Gillard, J. W., & Durkin, J. P. (2006). Preclinical Characterization of AEG35156/GEM 640, a Second-Generation Antisense Oligonucleotide Targeting X-Linked Inhibitor of Apoptosis. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-06-0608

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.